Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Inclusion Criteria: * Provided signed written informed consent. * Males and females \>=18 years of age. * Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and BRAF V600E/K mutation-positive from the designated qualified laboratory for this study. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate baseline organ function defined by: Absolute neutrophil count (ANC): \>=1,200 /microliter (uL); Hemoglobin: \>=9 grams (g)/deciliter (dL); Platelets: \>=100,000 /uL; Prothrombin time/ International normalization ratio and activated partial thromboplastin time: \<=1.3 x Upper Limit of Normal (ULN); Total bilirubin: \<=1.5 x ULN; Aspartate aminotransferase and Alanine aminotransferase: \<=2.5 x ULN; Calculated creatinine clearance (Calculate creatinine clearance using standard Cockcroft-Gault formula): \>=50 milliliter (mL)/ minute (min) or 24-hour urine creatinine clearance\>=50 mL/min; Left ventricular Ejection fraction (LVEF): \>/= 50% LVEF in case there is no established Lower limit of normal (LLN) for a given institution. Exclusion Criteria: * Prior treatment with a BRAF inhibitor or a MEK inhibitor * Pregnant or Lactating female. * History of another malignancy. Subjects with any previous malignancy with confirmed activating RAS mutation at any time are not eligible. Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility. Exception: Subjects who have been disease-free for 5 years (except those with confirmed activating RAS mutations), or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. * Brain metastasis are excluded unless: All known lesions have been definitively treated with surgery or stereotactic surgery (whole-brain radiation may be given as adjuvant treatment), OR Brain lesion(s), if still present, must be confirmed stable (i.e., no increase in lesion size) for \>=12 weeks prior to enrollment (stability must be confirmed with two consecutive magnetic resonance image (MRI) or computed tomography (CT) scans with contrast, separated by \>6 weeks AND Asymptomatic with no corticosteroid requirements for \>=4 weeks prior to enrollment, AND No enzyme inducing anticonvulsants for \>=2 weeks prior to enrollment. In addition, for subjects that had brain metastases but currently have no evidence of disease (NED), NED for \>=12 weeks is required and must be confirmed by two consecutive scans, separated by \>=6 weeks, prior to enrollment. * Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures. * Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to enrolment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrolment. * Any prohibited medication(s). * Administration of an investigational study treatment within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment(s) in this study. * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO). * A history or evidence of cardiovascular risk including any of the following: Current LVEF \< Institutional LLN; a QTc interval corrected for heart rate \>=480 millisecond (msec) (using Bazett's formula); a history or evidence of current clinically significant uncontrolled arrhythmias; Exception: Subjects with atrial fibrillation controlled for \>30 days prior to enrollment are eligible; a history (within 6 months prior to enrollment) of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty; a history or evidence of current \>=Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines; treatment refractory hypertension defined as a blood pressure of systolic\>140 millimeters of mercury (mmHg) and/or diastolic \>90 mm Hg which cannot be controlled by anti-hypertensive therapy; subjects with intra-cardiac defibrillators; abnormal cardiac valve morphology (\>=Grade 2) documented by echocardiogram (subjects with grade 1 abnormalities \[i.e., mild regurgitation/stenosis\] can be entered on study). Subjects with moderate valvular thickening should not be entered on study. * Uncorrectable electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia, hypocalcaemia determined by blood chemistry), long QT syndrome or taking medicinal products known to prolong the QT interval. * A history of retinal vein occlusion (RVO) * History of interstitial lung disease or pneumonitis. * History of HIV infection. * History of Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. * Subjects with laboratory evidence of cleared HBV and/or HCV will be permitted, which defined as HBs antigen negative and HBV Deoxyribonucleic acid (DNA) negative; and HCV antibody is negative.